VXRT is trading around 68 cents per share, has limited analyst coverage, and comes with serious risk. But its lone analyst has a $2 price target, implying roughly 195% upside from current levels.
1 extracted signal · 1 resolved · 0 still active
MarketBeatIndependent analyst profile- Source published
- 26 Feb 2026, 03:00 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:24 UTC
AI-generated source summary
The video discusses Vaxart (VXRT), a biotech penny stock trading around $0.68. A single analyst has given it a price target of $2.00, indicating a potential 195% upside. The rationale behind this target is the company's pipeline of oral vaccines, with some drugs in clinical stages (Stage 2 and Stage 3). The successful FDA approval and market entry of these oral vaccines could significantly boost the company's valuation, as this is an under-covered area of the market.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.